Nanopath Secures $10M to Develop POC Diagnostics for Women’s Health
Nanopath will develop & commercialize a biosensing platform that aims to transform how women’s pelvic & gynecologic infections are diagnosed.
Read MorePosted by Andy Lundin | Aug 16, 2022 | Company News, Womens Health |
Nanopath will develop & commercialize a biosensing platform that aims to transform how women’s pelvic & gynecologic infections are diagnosed.
Read MorePosted by Andy Lundin | Aug 16, 2022 | Covid 19, Rapid Assays |
Researchers have created an easy-to-use diagnostic test for COVID infection that is more sensitive than commonly used at-home antigen tests.
Read MorePosted by Andy Lundin | Aug 11, 2022 | Uncategorized |
Natera has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.
Read MorePosted by Andy Lundin | Aug 9, 2022 | Colorectal |
The NCCN announced new guidelines calling for testing to be available to all patients diagnosed with colorectal cancer.
Read MorePosted by Andy Lundin | Aug 8, 2022 | Covid 19, Point-of-Care |
A new POC diagnostic device can simultaneously detect the presence of both SARS-CoV-2 RNA & antibodies against the virus in saliva.
Read More